Automate Your Wheel Strategy on LPCN
With Tiblio's Option Bot, you can configure your own wheel strategy including LPCN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LPCN
- Rev/Share 0.7863
- Book/Share 3.2004
- PB 0.9558
- Debt/Equity 0.0
- CurrentRatio 12.7142
- ROIC -0.3258
- MktCap 16576874.0
- FreeCF/Share -0.2282
- PFCF -13.5758
- PE -3.6323
- Debt/Assets 0.0
- DivYield 0
- ROE -0.2358
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025
Published: June 23, 2025 by: PRNewsWire
Sentiment: Neutral
SALT LAKE CITY , June 23, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics, today announced that it will host a virtual research and development (R&D) investor event on Wednesday, July 9, 2025 at 11:00 AM ET featuring Kristina M. Deligiannidis, MD (Zucker Hillside Hospital, Northwell Health, New York), who will join company management to discuss the current treatment landscape and unmet needs in postpartum depression (PPD).
Read More
Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology
Published: May 22, 2025 by: PRNewsWire
Sentiment: Neutral
SALT LAKE CITY , May 22, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that its development candidate LPCN 1148 for men with cirrhosis is featured in the "Hepatology Highlights" section of the June 2025 edition of Hepatology. The article "LPCN 1148: Rebuilding muscle memory in cirrhosis patients" was contributed by Dr. Kevin Harris of the Division of Gastroenterology and Hepatology, Mayo Clinic, Minnesota.
Read More
Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154
Published: March 26, 2025 by: PRNewsWire
Sentiment: Neutral
48 hour at-home dosing Patient dosing expected in Q2/2025 SALT LAKE CITY , March 26, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics, today announced the initiation of a Phase 3 trial for LPCN 1154 (oral brexanolone) which is in development for the treatment of postpartum depression (PPD). Based on observed comparable exposure of LPCN 1154 and the reference drug established in the pharmacokinetic (PK) bridge study, the company is initiating a phase 3 safety and efficacy study with expected first patient dosed in the second …
Read More
About Lipocine Inc. (LPCN)
- IPO Date 2013-10-22
- Website https://www.lipocine.com
- Industry Biotechnology
- CEO Mahesh V. Patel
- Employees 16